Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

recently reported that its lead drug, nimotuzumab, is in numerous trials internationally including a Phase III randomized trial in adult glioma and a Phase II/III randomized trial in patients with advanced pancreatic cancer. Data from the fully recruited Phase III trial in Europe in children with inoperable brain cancer, if positive, are expected to be submitted to the EMEA for marketing approval.

About AeroLEF(TM)

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. In contrast to fixed-dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive delivery system designed to enable patients to self-titrate. Using AeroLEF(TM), patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such f
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... James Sherley says he has been working towards ... since his days as a principal investigator at the Fox ... Sherley founded the ASCTC as a new Boston biotech ... property developed in Sherley’s research over the years since FCCC, ... (MIT), and more recently as a senior scientist at the ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... The “Molecular Diagnostic Market by ... INAAT, DNA Sequencing), End User (Hospital, Laboratories), & ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global molecular diagnostics ... the revenue and share analysis. , The global ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5
... SAN DIEGO, March 12 Sangart, Inc., a privately ... commercialization of oxygen therapeutics, today announced the receipt of ... This investment results from the exercise of warrants issued ... round initiated in 2007. The most recent investment ...
... 12 The United States, long the beneficiary of ... workers from leaving to pursue expanding opportunities in their ... 2009 Issues in Science and Technology .In ... Duke University and Harvard Law School, writes that ...
... March 12 Boston Scientific Corporation (NYSE: ... raised the Company,s rating outlook to stable from negative. ... bond rating to Ba1 from Ba2 and its liquidity ... credit rating at Ba1. Moody,s said the revised ...
Cached Biology Technology:Sangart, Inc. Completes Series F Funding Round 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3Moody's Raises Boston Scientific's Rating Outlook to Stable 2Moody's Raises Boston Scientific's Rating Outlook to Stable 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... Singapore (NUS) have discovered a new reproductive mode in ... eggs in live bamboo with narrow openings - which ... ( Raorchestes chalazodes ). This critically endangered frog is ... this novel reproductive strategy. The findings were published in ... the Linnean Society , in October 2014. , ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... allowing us to spot prey, vision keeps many animals, including ... and why is it easier for us to spot movement ... notice other things? The complexity of the neural network that ... new technology and support from the National Science Foundation, Claire ...
... One of the many advantages of maintaining a normal ... a healthy heart. Fat tissue is increasingly seen as more ... secretory organ that normally produces high levels of a cardioprotective ... people has long been a mystery, and now a team ...
... developing a cost-effective electronic monitoring system that will enable ... by allowing users to track water-quality data from these ... National Science Foundation (NSF) grant. "Our goal is ... conditions in the Chesapeake Bay, the sounds of North ...
Cached Biology News:The zebrafish's neural circuit prevents it from biting off more than it can chew 2Study finds fat hormone's long-sought link to heart protection 2Researchers developing real-time electronic monitoring for coastal waters 2
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
Biology Products: